NEW YORK (GenomeWeb News) – MediSapiens today announced that it and Bayer HealthCare Pharmaceuticals have reached an agreement to develop a platform for the analysis of cancer genomics data.
"Genomics data is increasingly used both in preclinical and clinical research, but lacks software tools that can be adapted to various research environments," Tommi Pisto, CEO of MediSapiens, said in a statement. "Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of oncology research at Bayer HealthCare Pharmaceuticals."
Financial and other terms were not disclosed.
MediSapiens is a startup bioinformatics firm based in Helsinki. It received $1 million in seed funding in the spring of 2010.